Cargando…
Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis
BACKGROUND: Although clozapine is the most efficacious medication for treatment-refractory schizophrenia, not all patients will have an adequate response. Optimising clozapine dose using therapeutic drug monitoring could therefore maximise response. AIMS: Using individual patient data, we undertook...
Autores principales: | Northwood, Korinne, Pearson, E., Arnautovska, U., Kisely, S., Pawar, M., Sharma, M., Vitangcol, K., Wagner, E., Warren, N., Siskind, Dan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201335/ https://www.ncbi.nlm.nih.gov/pubmed/36994656 http://dx.doi.org/10.1192/bjp.2023.27 |
Ejemplares similares
-
Prevalence of frailty in severe mental illness: findings from the UK Biobank
por: Warren, Nicola, et al.
Publicado: (2023) -
Clozapine levels and therapeutic response: using individual patient meta-analysis data for a ROC Curve analysis
por: Northwood, K., et al.
Publicado: (2023) -
A 40-year study of child maltreatment over the early life course predicting psychiatric morbidity, using linked birth cohort and administrative health data: protocol for the Childhood Adversity and Lifetime Morbidity (CALM) study
por: Kisely, Steve, et al.
Publicado: (2023) -
CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapine
por: Siskind, Dan, et al.
Publicado: (2021) -
Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST)
por: Siskind, Dan, et al.
Publicado: (2023)